| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Director, 10% Owner
1 company
Allan M. Fox is Director at RGNX. Allan M. Fox's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $220K at current prices.
Historically, Allan M. Fox's trades have earned a strong insider score of 71/100 across 3 rated trades. Over a 12-month horizon, all 3 of those trades were profitable, with an average 12-month return of +36.7%.
The RGNX filings lean toward selling, a net 161,102 shares.
Allan M. Fox has 16 Form 4 filings on record from September 2015 to May 2026, all as Director at Regenxbio (RGNX), 2015–2026.
The 29 reported transactions were 12 option or other derivative awards, 5 stock awards, 4 open-market sales and 4 gifts, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $6.1M.
The largest open-market sale was 112,869 shares of RGNX at an average $34.69 on December 23, 2021, about $3.9M. Twelve months later RGNX was down 36%.